Johnson & Johnson Reports Sustained Efficacy of IMAAVY for Generalized Myasthenia Gravis [TheStreet.com]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: TheStreet.com
that IMAAVY (nipocalimab-aahu) maintains disease control in adults with generalized myasthenia gravis through 120 weeks of follow-up. The comprehensive study tracked 153 antibody-positive patients, including individuals with anti-AChR and anti-MuSK antibodies. Significant Reductions in Symptom Burden During the 96-week open-label extension phase, IMAAVY drove notable clinical improvements. Patients achieved mean reductions of 6.47 points on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale and 5.97 points on the Quantitative Myasthenia Gravis (QMG) scale. These critical metrics assess how symptoms impact daily routines and overall muscle strength. The treatment also delivered distinct milestones in symptom management: Half of the trial participants achieved minimal symptom expression. Nearly one-third of the patient population maintained this minimal symptom status for at least eight weeks. IMAAVY enabled 57% of patients to reach low corticosteroid doses of 1
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG) [Yahoo! Finance]Yahoo! Finance
- IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG) [TheStreet.com]TheStreet.com
- IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)PR Newswire
- Johnson & Johnson Announces CE Mark Approval for the New ETHICON™ 4000 Stapler [Yahoo! Finance]Yahoo! Finance
- ????????????????????????????(2025?~2035?) [CNET News]CNET News
JNJ
Earnings
- 4/14/26 - Beat
JNJ
Sec Filings
- 4/14/26 - Form 8-K
- 3/26/26 - Form SCHEDULE
- 3/18/26 - Form 13F-HR/A
- JNJ's page on the SEC website